Surgical optogenetic bioprinting of engineered cardiac muscle

LIGHTHEART aims to revolutionize heart failure treatment by developing a surgical bioprinting tool that uses optogenetics to create engineered cardiac muscle directly at the patient's heart.

Subsidie
€ 1.499.705
2023

Projectdetails

Introduction

Heart failure remains a leading cause of mortality worldwide, taking an estimate of 16 million lives each year. Cardiac tissue engineering solutions that can improve the quality of life of those with advanced heart disease have proved challenging so far.

Bioprinting Technology

Bioprinting is an exciting technology that holds promise to fabricate tissues and organs. Lab-grown engineered cardiac muscle requires at least four weeks to mature in a bioreactor.

Project Overview

In LIGHTHEART, an off-the-shelf solution will be developed for treating injured myocardium in vivo. An unconventional combination of bioprinting and optogenetics will be used to surgically fabricate engineered cardiac muscle directly at the patient’s heart.

Surgical Bioprinting Tool

A surgical bioprinting tool will be constructed to achieve vascularization and cellular architectures as observed in native cardiac muscle. Induced pluripotent stem cell-derived cardiac cells will be the basis of the bioinspired biomaterial-free ink that will be printed.

Optogenetic Expression

Optogenetic expression of different light-sensitive proteins at the cell surfaces will be the sole trigger of cellular assembly, thus omitting the need to embed cells in hydrogels or printing in a supporting bath.

Testing Phases

Surgical optogenetic bioprinting will be first tested ex vivo using a silicone human phantom with a mimicking beating heart, and later in vivo in a large animal model in accordance with the 3R principles.

Impact and Future Directions

LIGHTHEART opens up new horizons in the way heart failure can be clinically treated and brings hope to patients who are desperately waiting for a heart transplantation.

Collaborative Efforts

The disruptive nature of LIGHTHEART will unite engineers, surgeons, and scientists to change the future of transplantation medicine with modular bottom-up technologies that allow for in vivo tissue and organ restoration or replacement directly at the operating theatre.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 1.499.705
Totale projectbegroting€ 1.499.705

Tijdlijn

Startdatum1-3-2023
Einddatum29-2-2028
Subsidiejaar2023

Partners & Locaties

Projectpartners

  • RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGpenvoerder

Land(en)

Germany

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Computationally and experimentallY BioEngineeRing the next generation of Growing HEARTs

G-CYBERHEART aims to develop innovative experimental and computational methods for creating adaptable bioengineered hearts to improve treatment for congenital heart disease.

€ 1.497.351
ERC Consolid...

3D-assembly of interactive microgels to grow in vitro vascularized, structured, and beating human cardiac tissues in high-throughput

HEARTBEAT aims to create personalized, vascularized millimeter-scale heart tissues using innovative microgel assemblies to enhance stem cell interactions and mimic native environments.

€ 2.969.219
ERC Advanced...

Advanced human models of the heart to understand cardiovascular disease

Heart2Beat aims to develop innovative 3D human cardiac models using microfluidic technology to enhance understanding and treatment of cardiovascular diseases through personalized medicine.

€ 2.500.000
ERC Starting...

Nanorobotic microgels to control stem cell fate

Developing innovative microgel technology with nanorobotics to enhance stem cell differentiation for improved cardiac regeneration in myocardial infarction patients.

€ 1.500.000
ERC Consolid...

Piezoceutical biomaterial scaffolds for immunomodulatory-based myocardial repair

The PiezoMac patch aims to regenerate cardiac muscle post-myocardial infarction using optimized piezoelectric stimulation and 3D-printed designs tailored to patient-specific heart anatomy.

€ 2.579.608

Vergelijkbare projecten uit andere regelingen

EIC Pathfinder

High-throughput ultrasound-based volumetric 3D printing for tissue engineering

SONOCRAFT aims to revolutionize myocardial cell construct bioprinting by combining rapid volumetric printing with ultrasonic manipulation to create functional cardiac models for drug testing and disease research.

€ 2.999.625
EIC Pathfinder

Engineering a living human Mini-heart and a swimming Bio-robot

The project aims to develop advanced in vitro human cardiac models, including a vascularized mini-heart and a bio-robot, to better assess cardiotoxicity and improve understanding of cardiovascular disease.

€ 4.475.946
EIC Transition

Better Bioprinting by Light-sheet Lithography

B-BRIGHTER aims to develop a novel high-speed bioprinting technology for creating complex engineered tissues, enhancing drug testing and therapeutic applications while fostering healthcare innovation.

€ 2.093.331
EIC Transition

Bringing 3D cardiac tissues to high throughput for drug discovery screens

Developing a high-throughput 3D cardiac model using microfluidic technology to enhance drug discovery for cardiovascular disease by improving predictive accuracy and scalability.

€ 1.457.500
EIC Pathfinder

building vascular networks and Blood-Brain-Barriers through a Biomimetic manufacturing Technology for the fabrication of Human tissues and ORgans

THOR aims to revolutionize tissue engineering by creating patient-specific, fully functional human tissues using bioinspired mini-robots, eliminating the need for organ transplants.

€ 3.994.150